Sugi Predict

Sugi Predict / Compounds / SCHEMBL13282013

SCHEMBL13282013

SCHEMBL13282013

CC(C)(C)OC(=O)N1CCC(CCc2ccc(O)cc2)CC1

nearest known ligand 0.53

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 1/20 0.53
▸ FAAH O00519 2/20 0.52
▸ KDM4E B2RXH2 1/20 0.52
▸ PKM P14618 1/20 0.52
▸ GPR119 Q8TDV5 10/20 0.51
▸ TGFBR1 P36897 1/20 0.51
▸ PTPN2 P17706 1/20 0.47
▸ PTPN1 P18031 1/20 0.47
▸ PTPN6 P29350 1/20 0.47
▸ TP53 P04637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20015389 0.90 GPR119 (0.60) MAOBFAAHKDM4EPKMGPR119
SCHEMBL30824890 0.90 GPR119 (0.58) FAAHKDM4EPKMGPR119PTPN2
SCHEMBL14783164 0.88 FAAH (0.51) FAAHKDM4EPKMGPR119PTPN2
SCHEMBL17275272 0.88 FAAH (0.51) FAAHKDM4EPKMGPR119PTPN2
SCHEMBL20015575 0.88 FPR2 (0.53) FAAHKDM4EPKMGPR119PTPN2
SCHEMBL20015397 0.88 FAAH (0.66) MAOBFAAHKDM4EPKMGPR119
SCHEMBL4152084 0.88 MAOB (0.52) MAOBFAAHKDM4EPKMGPR119
SCHEMBL1912705 0.88 KDM4E (0.62) MAOBFAAHKDM4EPKMGPR119
SCHEMBL12263494 0.88 KDM4E (0.53) KDM4EPKMGPR119TGFBR1PTPN2
SCHEMBL12736015 0.87 KDM4E (0.56) FAAHKDM4EPKMGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388575-A1 HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE HALDA THERAPEUTICS OPCO INC (US) 2025-12-25 — — US disclosed
WO-2024054955-A1 HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE HALDA THERAPEUTICS OPCO, INC. (US) 2024-03-14 — — WO disclosed
WO-2024054955-A1 HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE HALDA THERAPEUTICS OPCO, INC. (US) 2024-03-14 — — WO disclosed
US-11597702-B2 Substituted pyrazoles FFA4/GPR120 receptor agonists GOLGI NEUROSCIENCES S.R.L. (IT) 2023-03-07 — — US disclosed
US-20210221785-A1 AMINO-PYRIMIDONYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM VERNALIS (R&D) LTD (GB) 2021-07-22 — — US disclosed
EP-3818054-A1 AMINO-PYRIMIDONYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Les Laboratoires Servier (FR) 2021-05-12 — — EP disclosed
US-20210087148-A1 SUBSTITUTED PYRAZOLES FFA4/GPR120 RECEPTOR AGONISTS GOLGI NEUROSCIENCES S.R.L. (IT) 2021-03-25 — — US disclosed
CN-112368276-A Amino-pyrimidinone derivatives, process for their preparation and pharmaceutical compositions containing them 法国施维雅药厂 2021-02-12 — — CN disclosed
EP-3765446-A1 SUBSTITUTED PYRAZOLES FFA4/GPR120 RECEPTOR AGONISTS AXXAM S.p.A. (IT) 2021-01-20 — — EP disclosed
CN-111868035-A Substituted pyrazole FFA4/GPR120 receptor agonists 阿克萨姆股份公司 2020-10-30 — — CN disclosed
WO-2020008013-A1 AMINO-PYRIMIDONYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LES LABORATOIRES SERVIER (FR) 2020-01-09 — — WO disclosed
WO-2019175152-A1 SUBSTITUTED PYRAZOLES FFA4/GPR120 RECEPTOR AGONISTS AXXAM S.P.A. (IT) 2019-09-19 — — WO disclosed
EP-2697232-B1 6,7-DIHYDROIMIDAZO[2,1-B][1,3]OXAZINE BACTERICIDES OTSUKA PHARMA CO LTD (JP) 2016-05-18 — — EP disclosed
US-9051333-B2 6,7-dihydroimidazo [2,1-b] [1,3]oxazine bactericides OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2015-06-09 — — US disclosed
EP-2697232-A1 6,7 - DIHYDROIMIDAZO [2, 1 - B][1, 3]OXAZINE BACTERICIDES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-02-19 — — EP disclosed
US-20140031342-A1 6,7-DIHYDROIMIDAZO [2,1-b] [1,3]OXAZINE BACTERICIDES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-01-30 — — US disclosed
WO-2012141338-A1 6,7 - DIHYDROIMIDAZO [2, 1 - B] [1, 3] OXAZINE BACTERICIDES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-10-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388575-A1 HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, CBR1 MAOB 776/4885FAAH 3529/4885KDM4E 2680/4885
US-20210087148-A1 SUBSTITUTED PYRAZOLES FFA4/GPR120 RECEPTOR AGONISTS FFAR4, FFAR3, FFAR1 MAOB 2801/4885FAAH 376/4885KDM4E 3733/4885
US-20210221785-A1 AMINO-PYRIMIDONYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DHFR, QDPR, DPYD MAOB 345/4885FAAH 4360/4885KDM4E 1861/4885
US-11597702-B2 Substituted pyrazoles FFA4/GPR120 receptor agonists FFAR4, FFAR3, FFAR1 MAOB 2801/4885FAAH 376/4885KDM4E 3733/4885
US-20140031342-A1 6,7-DIHYDROIMIDAZO [2,1-b] [1,3]OXAZINE BACTERICIDES BRD1, OXA1L, QDPR MAOB 941/4885FAAH 1216/4885KDM4E 3416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.